FDAnews Device Daily Bulletin

MIV THERAPEUTICS' BREAKTHROUGH VASCULAR STENT COATING TECHNOLOGY RECEIVES KEY INDEPENDENT ENDORSEMENT IN NEW SCIENTIFIC STUDY

June 7, 2006
A A

MIV Therapeutics , a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced June 5 that the safety and biocompatibility of its proprietary Hydroxyapatite (HAp) vascular stent coating technology has received pivotal independent confirmation in a new study conducted by a team of researchers in Italy and published in the renowned Journal of Biomedical Materials Research, a prestigious international journal of materials sciences.
MIV Therapeutics